The CAIX targeting radiotracer 68 Ga-C1 was developed and validated through in vitro assays. Initially, the investigators ...
Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...
Merck (NYSE:MRK) reported new Phase 3 data for belzutifan based WELIREG regimens in renal cell carcinoma, showing meaningful ...
We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...
HOW TO TAKE THE POST-TEST: To obtain CME credit, please click here after reading the article to take the post-test on myCME.com. Nephrologists routinely use biopsy of the kidney for making diagnoses ...
The PET tracer [ 89 Zr]Zr-girentuximab targets carbonic anhydrase IX (CAIX), a hypoxia-inducible enzyme that is strongly expressed in clear cell renal cell carcinoma (ccRCC). CAIX expression is highly ...
KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced ...
MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible. “Traditionally, radical nephroueterectomy has been the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results